Please join us for this on demand webinar, at which you will learn how protein biomarkers are providing an improve understanding and characterization of cancer patients stratification within Immuno-Oncology.
Professor Antoine Italiano (Head of Early Phase Trials and Sarcoma Unit, Institut Bergonié) will present Identification of predictive biomarkers of immunotherapy efficacy in cancer patients through analysis of plasma proteomics.
Also gain access to Professor Antoine Italiano's publication, 'Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel
predictive biomarker of immune-checkpoint blockade resistance.'
Professor Antoine Italiano (Head of Early Phase Trials and Sarcoma Unit, Institut Bergonié)
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.